Effects of electrochemotherapy on immunologically important modifications in tumor cells

Kešar, Urša (avtor), Markelc, Boštjan (avtor), Jesenko, Tanja (avtor), Uršič Valentinuzzi, Katja (avtor), Čemažar, Maja (avtor), Strojan, Primož (avtor), Serša, Gregor (avtor)

Electrochemotherapy (ECT) is a clinically acknowledged method that combines the use of anticancer drugs and electrical pulses. Electrochemotherapy with bleomycin (BLM) can induce immunogenic cell death (ICD) in certain settings. However, whether this is ubiquitous over different cancer types and for other clinically relevant chemotherapeutics used with electrochemotherapy is unknown. Here, we evaluated in vitro in the B16-F10, 4T1 and CT26 murine tumor cell lines, the electrochemotherapy triggered changes in the ICD-associated damage-associated molecular patterns (DAMPs): Calreticulin (CRT), ATP, High Mobility Group Box 1 (HMGB1), and four immunologically important cellular markers: MHCI, MHC II, PD-L1 and CD40. The changes in these markers were investigated in time up to 48 h after ECT. We showed that electrochemotherapy with all three tested chemotherapeutics induced ICD-associated DAMPs, but the induced DAMP signature was cell line and chemotherapeutic concentration specific. Similarly, electrochemotherapy with CDDP, OXA or BLM modified the expression of MHC I, MHC II, PD-L1 and CD40. The potential of electrochemotherapy to change their expression was also cell line and chemotherapeutic concentration specific. Our results thus put the electrochemotherapy with clinically relevant chemotherapeutics CDDP, OXA and BLM on the map of ICD inducing therapies.

• Jezik: Angleški jezik
• Ključne besede: electrochemotherapy, cisplatin, immune response, oxaliplatin, bleomycin, immunogenic cell death, ATP, HMGB1, calreticulin
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: MF - Medicinska fakulteta ; BF - Biotehniška fakulteta ; ZF - Zdravstvena fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2023
• Št. strani: 24 str.
• Številčenje: Vol. 11, iss. 5, art. 925
• PID: 20.500.12556/RUL-164871
• UDK: 602
• ISSN pri članku: 2076-393X
• DOI: 10.3390/vaccines11050925
• COBISS.SI-ID: 151344131
• Datum objave v RUL: 14.11.2024

Gradivo je del revije

• Naslov: Vaccines
• Skrajšan naslov: Vaccines
• Založnik: MDPI
• ISSN: 2076-393X
• COBISS.SI-ID: 520262937

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: elektrokemoterapija, cisplatin, imunski odgovor

Projekti

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: Z3-2651
• Naslov: Elektrokemoterapija kot in situ vakcinacija

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: P3-0003
• Naslov: Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev